STOCKHOLM, April 24, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the first quarter 2024, in conjunction with their partner Biogen's first quarter report. In total, sales of JPY 2.83 billion were recorded in the period, resulting in a royalty to BioArctic amounting to approximately SEK 18 million.
STOCKHOLM, April 20, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exercise an option to license BAN2802 for the treatment of Alzheimer's disease.
STOCKHOLM, April 16, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic AB (publ) presents the following proposals regarding the resolution on the number of board members and the election of board members and Chairperson of the Board at the Annual General Meeting on May 22, 2024.
STOCKHOLM, April 10, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA-B) (STOCKHOLM: BIOA-B) commitment to its Sustainable Innovation approach - combining scientific progress with responsible business practices and a dedication to environmental, social, and corporate governance principles (ESG) - has earned the company a place on the new Nasdaq OMX Sweden Small Cap 30 ESG Responsibility Index (OMXSS30ESGGI) launched today.
STOCKHOLM, April 1, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: Leqembi®) intravenous (IV) maintenance dosing to the U.S. Food and Drug Administration (FDA). Leqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment or mild dementia stage of disease (collectively referred to as early AD).
March 22 (Reuters) - The European Union's medicines regulator has delayed its decision on Eisai (4523.T), opens new tab and partner Biogen's (BIIB.O), opens new tab Alzheimer's disease drug that was expected this week, the Japanese company said on Friday.
STOCKHOLM, March 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (STO: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, was awarded the European Grand Prix for his research on Alzheimer's disease at the anniversary gala for La Fondation Recherche Alzheimer in Paris on March 18. The prize was presented by the President of France, Emmanuel Macron.
BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress
BioArctic's partner Eisai presents sales simulation for Leqembi
STOCKHOLM, Feb. 6, 2024 /PRNewswire/ -- BioArctic AB's (publ) (STO: BIOA-B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2023 (third quarter of Eisai's fiscal year, ending March 2024). In total, sales of JPY 1.1 billion were recorded in the period, resulting in a royalty to BioArctic amounting to SEK 7.3 million.